跳至主要内容
临床试验/NCT05749289
NCT05749289招募中2 期

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2022年12月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
400
试验地点
1
主要终点
Diagnostic value

研究概览

简要总结

This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors

详细描述

Octreotide is an artificial replacement for the natural growth hormone inhibitor in humans. It is a small peptide hormone consisting of 14 amino acids and is widely distributed in neuroendocrine cells, with the highest density in the brain, peripheral neurons, endocrine pancreas and gastrointestinal tract. Under pathological conditions, some tumour cells show overexpression of growth inhibitory receptors, such as endocrine tumours of the pancreas, pituitary adenomas, pheochromocytomas, paragangliomas, carcinoid tumours, medullary thyroid carcinomas, small cell lung carcinomas Hepatocellular carcinoma, and meningioma. Therefore, the sensitivity and specificity of octreotide imaging is high.

This study will provide a visual, reproducible and non-invasive imaging method for the diagnosis of SSTR positive tumors through Al18F-octreotide PCT/CT imaging, providing an intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment, contributing to the development of medicine and science in the field of positron imaging.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with suspected or clearly diagnosed SSTR positive tumors
  • signed written consent.
  • Willing and able to cooperate with all projects in this study.

排除标准

  • pregnancy;
  • breastfeeding;
  • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

研究组 & 干预措施

Al18F-octreotide PET/CT

Experimental

Al18F-octreotide PET/CT will be performed on patients with suspected or clearly diagnosed SSTR positive tumors . The patients were injected with Al18F-octreotide and underwent PET/CT scan 20~40min after the injection.

干预措施: Al18F-octreotide (Drug)

结局指标

主要结局

Diagnostic value

时间窗: through study completion, an average of 1 year]

Sensitivity and Specificity of Al18F-octreotide PET/CT for SSTR positive tumors

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验